Research programme: eye disorder therapeutics - BiomX/Oyster Point Pharma
Latest Information Update: 05 Apr 2024
At a glance
- Originator Naval Medical Research Center
- Class Bacteriophages; Eye disorder therapies
- Mechanism of Action Bacterial growth inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Eye disorders